Companion Diagnostic Reagent Testing: Technical Overview, Methods, and Applications

Companion diagnostic reagent testing is a specialized form of in vitro diagnostic (IVD) testing that identifies biomarkers essential for the safe and effective use of targeted therapeutic products. By linking patient selection to specific drug response, companion diagnostics form the foundation of precision medicine, particularly in oncology. This article provides a comprehensive technical overview of companion diagnostic reagent testing, covering sample types, biomarkers, analytical methods, applications, and frequently asked questions.

Technical Overview

Companion diagnostic reagents are in vitro diagnostic devices or assays that provide information essential for the safe and effective use of a corresponding therapeutic product, typically a targeted drug or biologic. Unlike general-purpose laboratory tests, companion diagnostics are analytically and clinically validated in direct association with a specific therapy, enabling clinicians to identify patients who are most likely to benefit from treatment, avoid therapy in patients unlikely to respond, or monitor for potential adverse reactions.

The core principle of companion diagnostic testing rests on the relationship between a measurable biomarker and a therapeutic outcome. A biomarker may be a gene mutation, gene amplification, chromosomal rearrangement, fusion transcript, protein overexpression, or genomic instability signature. When the presence, absence, or level of this biomarker is demonstrably linked to drug efficacy or safety, regulatory agencies such as the FDA, EMA, and NMPA may require or recommend the companion diagnostic as a condition for prescribing the associated therapy.

From a regulatory perspective, companion diagnostic reagents are typically classified as high-risk IVD products and are subject to rigorous requirements covering analytical sensitivity, analytical specificity, accuracy, precision, limit of detection, and clinical validity. Co-development strategies, in which the diagnostic assay and the drug are validated in parallel during clinical trials, have become the standard model for targeted therapy programs. Laboratories performing companion diagnostic testing must operate under quality management systems such as ISO 13485 for manufacturers, ISO 15189 for clinical laboratories, or CLIA certification, and must participate in external quality assessment and proficiency testing programs.

Testing Samples

Formalin-Fixed Paraffin-Embedded (FFPE) Tissue

FFPE tissue is the most widely used sample type for companion diagnostic testing in oncology. Surgical resection specimens, core needle biopsies, and fine-needle aspiration cell blocks are fixed in 10% neutral buffered formalin, processed, and embedded in paraffin wax. FFPE samples preserve tumor morphology, allowing pathologists to verify diagnosis and assess tumor cellularity prior to molecular testing. Key pre-analytical requirements include neutral-buffered formalin fixation for 6 to 48 hours, avoidance of decalcifying agents containing strong acids for bone specimens, and confirmation of adequate tumor content, typically a minimum of 10% to 20% tumor nuclei depending on the assay.

Fresh and Frozen Tissue

Fresh or flash-frozen tissue specimens offer superior nucleic acid quality and are preferred for certain assays, including RNA-based fusion detection and whole-genome or whole-exome sequencing protocols that are sensitive to formalin-induced fragmentation. Samples must be transported rapidly under controlled cold chain conditions to prevent degradation.

Peripheral Blood and Plasma

Whole blood collected in EDTA tubes is used for germline testing, such as BRCA1/BRCA2 mutation analysis for PARP inhibitor selection. Plasma-derived circulating tumor DNA (ctDNA) enables minimally invasive liquid biopsy testing for patients where tissue is unavailable or insufficient. ctDNA samples require specialized stabilization tubes or rapid plasma separation within a defined time window to minimize leukocyte DNA contamination.

Other Sample Types

• Bone marrow aspirates for hematologic malignancy testing
• Body cavity effusions and cytology preparations
• Oral rinse or buccal swab specimens for germline confirmation studies
• Archived tissue blocks with documented fixation history

Testing Items

Companion diagnostic reagent testing encompasses a broad range of biomarkers across multiple cancer types and therapeutic areas. Common testing targets include:

• HER2 protein overexpression and ERBB2 gene amplification for trastuzumab, pertuzumab, and trastuzumab deruxtecan in breast and gastric cancer
• EGFR activating mutations, including exon 19 deletions, L858R, and T790M resistance mutations, for EGFR tyrosine kinase inhibitors such as gefitinib, erlotinib, and osimertinib in non-small cell lung cancer
• ALK gene rearrangements for crizotinib, alectinib, and lorlatinib
• ROS1 and RET fusions for selective kinase inhibitors
• BRAF V600 mutations for vemurafenib, dabrafenib, and encorafenib in melanoma, lung, and colorectal cancer
• KRAS and NRAS mutations as negative predictors for anti-EGFR antibodies such as cetuximab and panitumumab in colorectal cancer
• KRAS G12C mutations for sotorasib and adagrasib
• PD-L1 protein expression for immune checkpoint inhibitors including pembrolizumab, nivolumab, and atezolizumab
• BRCA1 and BRCA2 pathogenic variants for PARP inhibitors such as olaparib and niraparib in ovarian, breast, prostate, and pancreatic cancer
• Microsatellite instability (MSI) and mismatch repair (MMR) protein deficiency for immunotherapy eligibility
• NTRK gene fusions for larotrectinib and entrectinib
• MET exon 14 skipping mutations and MET amplification for capmatinib and tepotinib
• PIK3CA mutations for alpelisib in hormone receptor-positive breast cancer
• Homologous recombination deficiency (HRD) scoring for PARP inhibitor response prediction
• Tumor mutational burden (TMB) as a pan-cancer immunotherapy biomarker

Testing Methods

Companion diagnostic testing employs multiple complementary analytical platforms, each suited to particular biomarker classes. Method selection depends on the analyte type, required sensitivity, sample availability, and the intended therapeutic indication.

Immunohistochemistry (IHC)

IHC detects protein expression in tissue sections using antigen-specific antibodies coupled to chromogenic or fluorescent detection systems. It is the standard method for HER2 status determination, PD-L1 expression scoring using validated clones and platform-specific scoring algorithms such as TPS and CPS, and MMR protein evaluation. IHC results are interpreted semi-quantitatively by trained pathologists according to validated scoring criteria.

Fluorescence In Situ Hybridization (FISH)

FISH uses labeled DNA probes to visualize gene copy number and structural rearrangements directly within tumor cell nuclei. It remains a reference method for confirming HER2 gene amplification, detecting ALK and ROS1 rearrangements, and evaluating MET amplification. Enumeration of signal patterns in a defined number of tumor nuclei yields amplification ratios or rearrangement percentages that are compared against validated cutoff values.

Polymerase Chain Reaction (PCR)

Real-time quantitative PCR, allele-specific PCR (such as ARMS or Scorpions technology), and reverse-transcription PCR are widely used for hotspot mutation detection, fusion transcript identification, and MSI analysis. PCR-based companion diagnostics offer high analytical sensitivity, often detecting mutant alleles at frequencies of 1% or below, rapid turnaround, and low sample input requirements. Digital PCR provides absolute quantification and enhanced sensitivity for low-frequency alleles in liquid biopsy applications.

Next-Generation Sequencing (NGS)

NGS enables simultaneous interrogation of dozens to hundreds of genes using targeted amplicon or hybrid-capture panels on formalin-fixed tissue or ctDNA. Comprehensive genomic profiling through NGS can identify single nucleotide variants, insertions and deletions, copy number alterations, and gene fusions in a single workflow, streamlining patient triage across multiple targeted therapy options. NGS-based tests require stringent bioinformatics pipelines, orthogonal validation of variant calls, and established analytical validity metrics.

Sanger Sequencing and Mass Spectrometry

Sanger sequencing serves as a confirmatory method for variants detected by screening assays and remains suitable for samples with high tumor allele fractions. Mass spectrometry-based genotyping, such as MALDI-TOF platforms, provides multiplexed mutation detection with rapid throughput in high-volume laboratory settings.

Applications

Companion diagnostic reagent testing is applied across virtually every discipline of precision oncology and increasingly in other therapeutic areas. Major applications include:

• Patient selection for targeted therapies in non-small cell lung cancer, breast cancer, colorectal cancer, melanoma, gastric cancer, ovarian cancer, prostate cancer, and hematologic malignancies
• Identification of patients unlikely to benefit from specific agents, such as RAS-mutant colorectal tumors excluded from anti-EGFR antibody therapy
• Eligibility screening for immune checkpoint inhibitor monotherapy or combination regimens based on PD-L1, MSI, or TMB status
• Resistance mechanism monitoring through serial liquid biopsy, including detection of EGFR T790M at progression
• Germline risk assessment and PARP inhibitor eligibility determination in hereditary cancer syndromes
• Pharmacogenomic applications beyond oncology, including HLA-B allele screening for drug hypersensitivity and enzyme genotyping for dose individualization
• Support for clinical trial enrollment through biomarker stratification and basket or umbrella study screening

Beyond direct clinical care, companion diagnostic reagent testing supports pharmaceutical development programs by enabling biomarker-driven clinical trial design, serving as an essential quality component of regulatory submissions, and facilitating post-market surveillance of assay performance.

FAQ

What distinguishes a companion diagnostic from a standard laboratory test?

A companion diagnostic is analytically and clinically validated in direct linkage with a specific therapeutic product, and its result determines patient eligibility for that therapy. Standard laboratory tests provide general diagnostic or prognostic information without a mandatory link to a particular drug label.

How long does companion diagnostic reagent testing take?

Turnaround time varies by methodology. IHC and PCR-based tests are typically completed within 3 to 5 working days, FISH within 5 to 7 working days, and comprehensive NGS panels generally within 7 to 14 working days, including pathology review and variant interpretation.

What if the tissue sample is insufficient or unavailable?

Liquid biopsy using plasma ctDNA offers a minimally invasive alternative when tissue cannot be obtained. However, a negative ctDNA result does not exclude the presence of a biomarker due to variable tumor shedding, and tissue testing is generally recommended for confirmation.

Are companion diagnostic results reproducible across laboratories?

Validated companion diagnostics demonstrate high inter-laboratory reproducibility when performed according to the approved protocol on the designated platform. Laboratories must adhere to standardized pre-analytical handling, participate in external quality assessment schemes, and maintain documented competency programs for personnel and interpretation.

What quality controls are required during testing?

Each analytical run must include positive and negative controls, internal amplification controls, and calibration materials traceable to reference standards. Acceptance criteria, invalid-run definitions, and corrective action procedures must be predefined in validated standard operating procedures.

How are equivocal results managed?

Equivocal or borderline results, such as HER2 IHC 2+ scores, require reflex confirmation by an orthogonal method, typically FISH. Retesting on an alternative specimen may be necessary when results are indeterminate due to pre-analytical degradation or suboptimal tumor content.